Garcia-Heras Jaime
The Journal of the Association of Genetic Technologists.
J Assoc Genet Technol. 2024;50(1):5-13.
The Nobel Prize in Physiology or Medicine for 2023 awarded to Dr. Katalin Karikó and Dr. Drew Weissman recognized their seminal discoveries in nucleoside modifications of messenger RNA that were pivotal to developing the first mRNA vaccines for clinical use in humans. These novel vaccines were key for prophylactic control of a pandemic caused by the new coronavirus SARS-CoV-2 that emerged abruptly in late 2019/early 2020. This breakthrough capped years of previous research in coronaviruses that included SARS- CoV and MERS-CoV associated with earlier human outbreaks, developments of more efficient formulations to deliver nucleic acids in vivo, and applications of a novel mRNA technology to generate a new generation of better vaccines cost-effectively. Such successful outcomes herald a wide range of advances with this highly adaptable mRNA technology. These include vaccines against existing infectious agents of medical significance but also emerging pathogens, cancer immunotherapies, and protein-replacement therapies, while at the same time, other uses are also under active investigation.
2023年诺贝尔生理学或医学奖授予卡塔琳·卡里科博士和德鲁·魏斯曼博士，以表彰他们在信使核糖核酸核苷修饰方面的开创性发现，这些发现对于开发首批用于人类临床的信使核糖核酸疫苗至关重要。这些新型疫苗对于预防由2019年末/2020年初突然出现的新型冠状病毒SARS-CoV-2引发的大流行至关重要。这一突破为此前多年针对冠状病毒的研究画上了圆满句号，这些研究包括与早期人类疫情相关的SARS-CoV和MERS-CoV、开发更有效的体内递送核酸制剂，以及应用新型信使核糖核酸技术经济高效地生产新一代更好的疫苗。如此成功的成果预示着这项高度适应性强的信使核糖核酸技术将带来广泛进展。这些进展包括针对具有医学意义的现有传染病原体以及新出现病原体的疫苗、癌症免疫疗法和蛋白质替代疗法，与此同时，其他用途也在积极研究中。
